Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Profile of men randomized to the prostate cancer prevention trial: baseline health-related quality of life, urinary and sexual functioning, and health behaviors.

Moinpour CM, Lovato LC, Thompson IM Jr, Ware JE Jr, Ganz PA, Patrick DL, Shumaker SA, Donaldson GW, Ryan A, Coltman CA Jr.

J Clin Oncol. 2000 May;18(9):1942-53.

PMID:
10784636
2.

Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention Trial.

Moinpour CM, Darke AK, Donaldson GW, Thompson IM Jr, Langley C, Ankerst DP, Patrick DL, Ware JE Jr, Ganz PA, Shumaker SA, Lippman SM, Coltman CA Jr.

J Natl Cancer Inst. 2007 Jul 4;99(13):1025-35. Epub 2007 Jun 27.

PMID:
17596576
3.

Minority recruitment in the prostate cancer prevention trial.

Moinpour CM, Atkinson JO, Thomas SM, Underwood SM, Harvey C, Parzuchowski J, Lovato LC, Ryan AM, Hill MS, Deantoni E, Gritz ER, Thompson IM Jr, Coltman CA Jr.

Ann Epidemiol. 2000 Nov;10(8 Suppl):S85-91.

PMID:
11189097
4.

Age-related changes in general and sexual health in middle-aged and older men: results from the European Male Ageing Study (EMAS).

Corona G, Lee DM, Forti G, O'Connor DB, Maggi M, O'Neill TW, Pendleton N, Bartfai G, Boonen S, Casanueva FF, Finn JD, Giwercman A, Han TS, Huhtaniemi IT, Kula K, Lean ME, Punab M, Silman AJ, Vanderschueren D, Wu FC; EMAS Study Group..

J Sex Med. 2010 Apr;7(4 Pt 1):1362-80. doi: 10.1111/j.1743-6109.2009.01601.x. Epub 2009 Nov 19.

PMID:
19929914
5.

Five-alpha-reductase Inhibitors for prostate cancer prevention.

Wilt TJ, MacDonald R, Hagerty K, Schellhammer P, Kramer BS.

Cochrane Database Syst Rev. 2008 Apr 16;(2):CD007091. doi: 10.1002/14651858.CD007091. Review.

PMID:
18425978
6.

Design of the Prostate Cancer Prevention Trial (PCPT).

Feigl P, Blumenstein B, Thompson I, Crowley J, Wolf M, Kramer BS, Coltman CA Jr, Brawley OW, Ford LG.

Control Clin Trials. 1995 Jun;16(3):150-63.

PMID:
7540965
7.

Health-related quality-of-life findings for the prostate cancer prevention trial.

Moinpour CM, Darke AK, Donaldson GW, Cespedes D, Johnson CR, Ganz PA, Patrick DL, Ware JE Jr, Shumaker SA, Meyskens FL, Thompson IM Jr.

J Natl Cancer Inst. 2012 Sep 19;104(18):1373-85. Epub 2012 Sep 12.

8.
9.

The effect of comorbidity and socioeconomic status on sexual and urinary function and on general health-related quality of life in men treated with radical prostatectomy for localized prostate cancer.

Karakiewicz PI, Bhojani N, Neugut A, Shariat SF, Jeldres C, Graefen M, Perrotte P, Peloquin F, Kattan MW.

J Sex Med. 2008 Apr;5(4):919-27. doi: 10.1111/j.1743-6109.2007.00741.x.

PMID:
18371045
10.

Psychosocial interventions for men with prostate cancer.

Parahoo K, McDonough S, McCaughan E, Noyes J, Semple C, Halstead EJ, Neuberger MM, Dahm P.

Cochrane Database Syst Rev. 2013 Dec 24;(12):CD008529. doi: 10.1002/14651858.CD008529.pub3. Review.

PMID:
24368598
11.

Sexual bother in men with advanced prostate cancer undergoing androgen deprivation therapy.

Benedict C, Traeger L, Dahn JR, Antoni M, Zhou ES, Bustillo N, Penedo FJ.

J Sex Med. 2014 Oct;11(10):2571-80. doi: 10.1111/jsm.12645. Epub 2014 Jul 24.

PMID:
25059094
12.

Finasteride for benign prostatic hyperplasia.

Tacklind J, Fink HA, Macdonald R, Rutks I, Wilt TJ.

Cochrane Database Syst Rev. 2010 Oct 6;(10):CD006015. doi: 10.1002/14651858.CD006015.pub3. Review.

PMID:
20927745
13.

Effect of finasteride on bother and other health-related quality of life aspects associated with benign prostatic hyperplasia. PLESS Study Group. Proscar Long-term Efficacy and Safety Study.

Bruskewitz R, Girman CJ, Fowler J, Rigby OF, Sullivan M, Bracken RB, Fusilier HA, Kozlowski D, Kantor SD, Johnson EL, Wang DZ, Waldstreicher J.

Urology. 1999 Oct;54(4):670-8.

PMID:
10510926
14.

Exercise therapy for chronic fatigue syndrome.

Larun L, Brurberg KG, Odgaard-Jensen J, Price JR.

Cochrane Database Syst Rev. 2016 Jun 24;(6):CD003200. doi: 10.1002/14651858.CD003200.pub5. Review. Update in: Cochrane Database Syst Rev. 2016 Dec 20;12 :CD003200.

PMID:
27339435
15.

Exercise therapy for chronic fatigue syndrome.

Larun L, Brurberg KG, Odgaard-Jensen J, Price JR.

Cochrane Database Syst Rev. 2016 Feb 7;2:CD003200. doi: 10.1002/14651858.CD003200.pub4. Review. Update in: Cochrane Database Syst Rev. 2016;(6):CD003200.

16.

Exercise therapy for chronic fatigue syndrome.

Larun L, Brurberg KG, Odgaard-Jensen J, Price JR.

Cochrane Database Syst Rev. 2015 Feb 10;(2):CD003200. doi: 10.1002/14651858.CD003200.pub3. Review. Update in: Cochrane Database Syst Rev. 2016;2:CD003200.

17.

Changes in sexual roles and quality of life for gay men after prostate cancer: challenges for sexual health providers.

Hart TL, Coon DW, Kowalkowski MA, Zhang K, Hersom JI, Goltz HH, Wittmann DA, Latini DM.

J Sex Med. 2014 Sep;11(9):2308-17. doi: 10.1111/jsm.12598. Epub 2014 May 30.

18.

General quality of life 2 years following treatment for prostate cancer: what influences outcomes? Results from the prostate cancer outcomes study.

Penson DF, Feng Z, Kuniyuki A, McClerran D, Albertsen PC, Deapen D, Gilliland F, Hoffman R, Stephenson RA, Potosky AL, Stanford JL.

J Clin Oncol. 2003 Mar 15;21(6):1147-54.

PMID:
12637483
19.

Lifestyle and health-related quality of life of men with prostate cancer managed with active surveillance.

Daubenmier JJ, Weidner G, Marlin R, Crutchfield L, Dunn-Emke S, Chi C, Gao B, Carroll P, Ornish D.

Urology. 2006 Jan;67(1):125-30.

PMID:
16413347
20.

Age and baseline quality of life at radical prostatectomy--who has the most to lose?

Brajtbord JS, Punnen S, Cowan JE, Welty CJ, Carroll PR.

J Urol. 2014 Aug;192(2):396-401. doi: 10.1016/j.juro.2014.02.045. Epub 2014 Feb 25.

PMID:
24582539

Supplemental Content

Support Center